Julian Hickling

TL;DR: Examination of the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 found vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV.

TL;DR: This study confirmed the safety and immunogenicity of the vaccine in a proportion of those patients vaccinated with TA-HPV, a live recombinant vaccinia virus expressing modified forms of the HPV-16 and -18 E6 and E7 proteins.

TL;DR: The results suggest that theTA-HPV vaccine may have an effect on HPV-positive vulval intraepithelial neoplasia/vaginal intraepIThelial neoperasia and that additional studies are warranted to develop an effective therapeutic vaccine.

TL;DR: Both IgG antibodies and proliferative responses against TA-CIN were elicited at all three doses and T-cell immunity against the HPV16 E6 and E7 oncoproteins was detected by IFN gamma ELISPOT in 8/11 evaluable subjects vaccinated with the 533 micro g dose.

TL;DR: Local immune infiltration may be a critical factor in potential responsiveness to vaccine therapy in HPV-associated neoplasia and should be carefully monitored in future placebo-controlled trials of immunotherapy for VIN.